Clinical Trial

Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Bleomycin has nowadays been more and more widely used in the sclerotherapy of LMs, which has been proven to be primarily dose dependent. The investigators aim to compare the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of LMs for pediatric patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-25.
Trial Details
NCT Number NCT06437158
Lead Sponsor West China Hospital
Conditions Lymphatic Malformation
Enrollment 200 participants
Start Date 2023-03-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-03